Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Clopidogrel and Aspirin for the Treatment of Polycythemia Vera

First Posted Date
2009-07-16
Last Posted Date
2014-11-26
Lead Sponsor
Ronald Hoffman
Registration Number
NCT00940784

Ex Vivo Human Thrombosis Chamber Study

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-07-09
Last Posted Date
2011-02-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
15
Registration Number
NCT00935506
Locations
🇺🇸

Mds Pharma Services, Neptune, New Jersey, United States

Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2009-05-12
Last Posted Date
2009-05-12
Lead Sponsor
University of Portsmouth
Target Recruit Count
21
Registration Number
NCT00898950
Locations
🇬🇧

School of Pharmacy and Biomedical Sciences, University of Posrtmouth, Portsmouth, Hampshire, United Kingdom

🇬🇧

Diabetes Centre, Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, Hampshire, United Kingdom

Effect of Daily Low Dose Aspirin on Exhaled Inflammatory Mediators in Normal Subjects

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2009-05-12
Last Posted Date
2015-09-25
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
4
Registration Number
NCT00898222
Locations
🇺🇸

Asthma Research Center, Brigham and Women's Hospital, Boston, Massachusetts, United States

Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events

First Posted Date
2009-04-23
Last Posted Date
2010-06-04
Lead Sponsor
Hanyang University
Target Recruit Count
400
Registration Number
NCT00886574
Locations
🇰🇷

Inha University Hospital, In Cheon, Korea, Republic of

🇰🇷

Hallym University Hospital, Seoul, Korea, Republic of

🇰🇷

Korea University Guro Hospital, Seoul, Korea, Republic of

and more 2 locations

The Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel in Normal Volunteers

First Posted Date
2009-04-16
Last Posted Date
2013-12-17
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
40
Registration Number
NCT00882388
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers

First Posted Date
2009-03-31
Last Posted Date
2015-08-11
Lead Sponsor
PLx Pharma
Target Recruit Count
204
Registration Number
NCT00872534
Locations
🇺🇸

Altoona Arthritis and Osteoporosis Center, Altoona, Pennsylvania, United States

🇺🇸

Jupiter Research, Jupiter, Florida, United States

🇺🇸

Miami Research Associates, South Miami, Florida, United States

and more 3 locations

Effects of Pioglitazone on Platelet Function

First Posted Date
2009-03-13
Last Posted Date
2016-02-03
Lead Sponsor
University of Rochester
Target Recruit Count
40
Registration Number
NCT00861341
Locations
🇺🇸

University of Rochester, Rochester, New York, United States

Resistance to Antithrombotic Therapy

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2009-03-10
Last Posted Date
2012-12-12
Lead Sponsor
Medical University of Vienna
Target Recruit Count
46
Registration Number
NCT00858715
Locations
🇦🇹

Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria

© Copyright 2024. All Rights Reserved by MedPath